$420 Million is the total value of Corriente Advisors, LLC's 19 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 157.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MAXR | Buy | MAXAR TECHNOLOGIES INC | $96,475,000 | +96.2% | 2,500,000 | +26.8% | 22.96% | -7.9% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $64,901,000 | +122.1% | 525,000 | +75.0% | 15.45% | +4.2% |
| REPL | Buy | REPLIMUNE GROUP INC | $47,115,000 | +299.3% | 1,235,000 | +141.0% | 11.22% | +87.4% |
| CRDF | Buy | CARDIFF ONCOLOGY INC | $35,980,000 | +178.6% | 2,000,000 | +119.8% | 8.56% | +30.8% |
| CCJ | New | CAMECO CORP | $29,173,000 | – | 2,177,086 | +100.0% | 6.94% | – |
| GPRO | New | GOPRO INCcl a | $27,738,000 | – | 3,350,000 | +100.0% | 6.60% | – |
| CUE | Buy | CUE BIOPHARMA INC | $23,959,000 | +10.7% | 1,915,219 | +33.2% | 5.70% | -48.0% |
| TFFP | Buy | TFF PHARMACEUTICALS INC | $19,332,000 | -1.1% | 1,350,000 | +27.5% | 4.60% | -53.6% |
| FEYE | New | FIREEYE INC | $15,911,000 | – | 690,000 | +100.0% | 3.79% | – |
| CMPS | New | COMPASS PATHWAYS PLCsponsored ads | $9,052,000 | – | 190,000 | +100.0% | 2.16% | – |
| CRIS | New | CURIS INC | $9,009,000 | – | 1,100,000 | +100.0% | 2.14% | – |
| CNCE | New | CONCERT PHARMACEUTICALS INC | $8,595,000 | – | 680,000 | +100.0% | 2.05% | – |
| DMAC | Buy | DIAMEDICA THERAPEUTICS INC | $8,182,000 | +164.4% | 806,900 | +10.5% | 1.95% | +24.2% |
| KTOS | New | KRATOS DEFENSE & SEC SOLUTIO | $5,486,000 | – | 200,014 | +100.0% | 1.31% | – |
| NXE | New | NEXGEN ENERGY LTD | $2,758,000 | – | 1,000,000 | +100.0% | 0.66% | – |
| ONCR | New | ONCORUS INC | $2,523,000 | – | 78,043 | +100.0% | 0.60% | – |
| OCUL | New | OCULAR THERAPEUTIX INC | $1,116,000 | – | 53,934 | +100.0% | 0.27% | – |
| QS | New | QUANTUMSCAPE CORP | $84,000 | – | 1,000 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CUE BIOPHARMA INC | 8 | Q3 2021 | 26.7% |
| MAXAR TECHNOLOGIES INC | 7 | Q2 2021 | 41.3% |
| REATA PHARMACEUTICALS INC | 6 | Q2 2021 | 29.6% |
| REPLIMUNE GROUP INC | 5 | Q2 2021 | 12.1% |
| APTOSE BIOSCIENCES INC | 5 | Q4 2020 | 18.7% |
| CARDIFF ONCOLOGY INC | 5 | Q2 2021 | 9.5% |
| DIAMEDICA THERAPEUTICS INC | 5 | Q2 2021 | 2.9% |
| TFF PHARMACEUTICALS INC | 4 | Q3 2021 | 15.2% |
| INVESCO QQQ TR | 3 | Q3 2022 | 94.7% |
| LANTERN PHARMA INC | 3 | Q3 2021 | 13.5% |
View Corriente Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cardiff Oncology, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cue Biopharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| TFF Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| NAUTILUS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| Maxar Technologies Inc. | November 26, 2019 | 2,920,750 | 4.9% |
| CATABASIS PHARMACEUTICALS INC | February 23, 2018 | 1,692,899 | 7.3% |
| NEUROLOGIX INC/DE | February 14, 2011 | 16,858,224 | 37.7% |
| AMERICAN VANTAGE COMPANIESSold out | February 16, 2010 | 0 | 0.0% |
| AspenBio Pharma, Inc.Sold out | February 16, 2010 | 0 | 0.0% |
View Corriente Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-15 |
| SC 13G/A | 2022-02-14 |
View Corriente Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.